Nicox gains on Phase III glaucoma data

Nicox S.A. (Euronext:COX) gained EUR 0.46 (21%) to EUR 2.62 on Thursday after it said Vesneo latanoprostene bunod (formerly NCX 116, BOL-303259-X) met its primary endpoint of non-inferiority vs. timolol maleate in two Phase III trials to treat glaucoma and ocular hypertension. The primary endpoint was reduction of mean diurnal intraocular pressure (IOP) as measured at specified time points.

Vesneo also was statistically superior (p=<0.05) to timolol maleate in the Phase III APOLLO and LUNAR trials in reducing mean diurnal IOP during three months of treatment. The once-daily small molecule reduced IOP by 7.5 to 9.1 mmHg from baseline between 2 and 12 weeks of treatment. ...